hsa-miR-223

ncRNA information

ncRNA name

hsa-miR-223

Specific or universal ncRNAs

Universal ncRNAs

Class

MicroRNA

Biomarker

Yes

Biomarker application

Treatment

Upstream regulatory factors

Not available

Downstream target

FBW7

Cancer information

Cancer name

Hepatocellular Carcinoma

Cancer site

Liver

Treatment information

Treatment type

Chemotherapy

Drug

Sorafenib

Impact of wild-type ncRNA on chemotherapy resistance

Impact of knockdown of ncRNA on chemotherapy resistance

Down

Impact of overexpression of ncRNA on chemotherapy resistance

Clinical Information

ncRNA differential expression in
cancer patients vs. healthy people

Not available

Number of patients

Not available

Male patients

Not available

Female patients

Not available

Age range and number

Not available

Research information

PMID

Description

MiR-223 expression is upregulated in sorafenib-resistant HCC cells, and miR-223 knockdown significantly enhances HCC cell sensitivity to sorafenib by increasing expression of the target gene, FBW7, suggesting that miR-223 may be a new therapeutic target for overcoming sorafenib resistance.

Tissue resource

human hepatocellular carcinoma cell lines Huh7

human hepatocellular carcinoma cell lines SNU387

human hepatocellular carcinoma cell lines SNU449

Experiment

qRT-PCR,Western blot


Institute

the Cell Bank of the Type Culture Collection of Chinese Academy of Sciences

Country

China

Continent

Asia